Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,265
archived clinical trials in
Crohns Disease

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1142
mi
from
La Jolla, CA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1142
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
407
mi
from
Denver, CO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
407
mi
from
Denver, CO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
408
mi
from
Littleton, CO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
408
mi
from
Littleton, CO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1345
mi
from
Hamden, CT
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1345
mi
from
Hamden, CT
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1127
mi
from
Washington,
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1127
mi
from
Washington,
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1133
mi
from
Port Orange, FL
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1133
mi
from
Port Orange, FL
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
809
mi
from
Suwanee, GA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
809
mi
from
Suwanee, GA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
611
mi
from
Chicago, IL
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
611
mi
from
Chicago, IL
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1124
mi
from
Chevy Chase, MD
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1124
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1147
mi
from
Towson, MD
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1147
mi
from
Towson, MD
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
862
mi
from
Chesterfield, MI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
862
mi
from
Chesterfield, MI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
203
mi
from
Lee's Summit, MO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
203
mi
from
Lee's Summit, MO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
335
mi
from
Mexico, MO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
335
mi
from
Mexico, MO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1288
mi
from
Brooklyn, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1288
mi
from
Brooklyn, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1301
mi
from
Lake Success, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1301
mi
from
Lake Success, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1333
mi
from
Stony Brook, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1333
mi
from
Stony Brook, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
957
mi
from
Charlotte, NC
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
815
mi
from
Columbus, OH
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
815
mi
from
Columbus, OH
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
152
mi
from
Tulsa, OK
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
152
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1384
mi
from
Portland, OR
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1384
mi
from
Portland, OR
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
974
mi
from
Pittsburgh, PA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
618
mi
from
Nashville, TN
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
618
mi
from
Nashville, TN
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
790
mi
from
Ogden, UT
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
790
mi
from
Ogden, UT
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
954
mi
from
Christiansburg, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
954
mi
from
Christiansburg, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1016
mi
from
Danville, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1016
mi
from
Danville, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1186
mi
from
Norfolk, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1186
mi
from
Norfolk, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
574
mi
from
Madison, WI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
574
mi
from
Madison, WI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
632
mi
from
Milwaukee, WI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
632
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Bankstown,
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Bankstown,
Click here to add this to my saved trials
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
Status: Enrolling
Updated:  2/5/2018
University of California at Los Angeles
1177
mi
from
Los Angeles, CA
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
Status: Enrolling
Updated: 2/5/2018
University of California at Los Angeles
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford
1329
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford
1329
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Effect of Increlex® on Children With Crohn Disease
Effect of Increlex® on Children With Crohn Disease
Status: Enrolling
Updated:  2/23/2018
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Effect of Increlex® on Children With Crohn Disease
Effect of Increlex® on Children With Crohn Disease
Status: Enrolling
Updated: 2/23/2018
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
University of Florida
1049
mi
from
Gainesville, FL
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
University of Florida
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Rochester General Hospital
1123
mi
from
Rochester, NY
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Rochester General Hospital
1123
mi
from
Rochester, NY
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Baylor College of Medicine
569
mi
from
Houston, TX
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Baylor College of Medicine
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
University of Utah
777
mi
from
Salt Lake City, UT
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
University of Utah
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Cedars-Sinai Medical Center - Inflammatory Bowel Disease Center
1168
mi
from
Los Angeles, CA
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Cedars-Sinai Medical Center - Inflammatory Bowel Disease Center
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
University of Colorado- Health Science Center
407
mi
from
Denver, CO
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
University of Colorado- Health Science Center
407
mi
from
Denver, CO
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
University of Miami School of Medicine
1321
mi
from
Miami, FL
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
University of Miami School of Medicine
1321
mi
from
Miami, FL
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
University of Cincinnati Medical Center
724
mi
from
Cincinnati, OH
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
University of Cincinnati Medical Center
724
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Case Western Reserve University Hospitals of Cleveland
899
mi
from
Cleveland, OH
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Case Western Reserve University Hospitals of Cleveland
899
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
McGuire Veterans Affairs Medical Center
1110
mi
from
Richmond, VA
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
McGuire Veterans Affairs Medical Center
1110
mi
from
Richmond, VA
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated:  2/27/2018
Erlanger Baroness Hospital
719
mi
from
Chattanooga, TN
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Status: Enrolling
Updated: 2/27/2018
Erlanger Baroness Hospital
719
mi
from
Chattanooga, TN
Click here to add this to my saved trials
The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Status: Enrolling
Updated:  2/27/2018
Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
1290
mi
from
New York, NY
The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Status: Enrolling
Updated: 2/27/2018
Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
1168
mi
from
Los Angeles, CA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
1043
mi
from
Chapel Hill, NC
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials